XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1

ALLIANCES - Additional Information (Details) - SystImmune $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Alliance Statement [Line Items]
Upfront fee made to collaborative partner	$ 800
Consideration for contingent development and regulatory approval	$ 7,600

X

- Definition

This element represents that additional aggregate consideration for contingent development and regulatory approval milestone payments.

+ References

No definition available.

+ Details

Name:	bmy_ConsiderationForContingentDevelopmentAndRegulatoryApproval
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront payments made to partner as part of collaborative arrangement.

+ References

No definition available.

+ Details

Name:	bmy_UpfrontFeeMadeToCollaborativePartner
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	bmy_AlliancesAndCollaborationCompaniesAxis=bmy_SystImmuneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: